Novo Nordisk moved to undercut Eli Lilly on obesity drugs for cash-pay patients, offering introductory doses of Wegovy and Ozempic for $199 a month starting Monday. The price covers the first two months, after which the medicines will be sold through the company’s NovoCare direct-to-consumer portal for $349 a month—about 30% below the current self-pay rate. The $349 price matches Lilly’s low-dose Zepbound and comes in below higher-dose options, signaling Novo’s bid to reclaim US market share.

Prepared by Christopher Adams and reviewed by editorial team.